Magaraggia I, Krauskopf J, Ramaekers J G, You Y, de Nijs L, Briedé J J, Schreiber R
Department of Toxicogenomics, Faculty of Health, Medicine and Life Science, Maastricht University, P.O. 616, 6200, Maastricht, the Netherlands.
Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. 616, 6200 MD, Maastricht, the Netherlands.
Neurosci Appl. 2024 Dec 15;4:105406. doi: 10.1016/j.nsa.2024.105406. eCollection 2025.
The Research Domain Criteria (RDoC) framework offers a dimensional and transdiagnostic approach to understanding complex neuropsychiatric and neurological disorders, facilitating the development of novel therapeutics. However, the integration of cellular and molecular brain processes into the RDoC framework is hindered by the lack of adequate biomarkers. This review explores the potential of brain-derived extracellular vesicles (BDEVs) isolated from biofluids as a source of non-invasive mechanistic biomarkers in RDoC-based drug discovery. We provide an overview of BDEVs, including their classification, biological functions, and current methodologies for isolation and characterization. We then discuss studies that have investigated BDEV cargo as mechanistic biomarkers in CNS drug studies, focusing on target engagement, treatment response, and toxicity. Additionally, we address important considerations and open questions regarding the characterization and validation of BDEVs in neuroscience research. Special emphasis is placed on the use of miRNA cargo within BDEVs as molecular readouts, highlighting their stability, regulatory roles, and potential to reflect dynamic changes in brain function. Finally, the review proposes strategies to further investigate the use of BDEV miRNA cargo as molecular readouts, underscoring its ability to provide insights into the molecular mechanisms underlying drug effects and their relevance to CNS drug discovery within the RDoC framework. Despite existing methodological and conceptual challenges, BDEVs represent a promising tool for advancing RDoC-based drug discovery.
研究领域标准(RDoC)框架提供了一种维度和跨诊断的方法来理解复杂的神经精神和神经疾病,促进新型疗法的开发。然而,由于缺乏足够的生物标志物,细胞和分子脑过程融入RDoC框架受到阻碍。本综述探讨了从生物流体中分离的脑源性细胞外囊泡(BDEV)作为基于RDoC的药物发现中非侵入性机制生物标志物来源的潜力。我们概述了BDEV,包括它们的分类、生物学功能以及当前的分离和表征方法。然后,我们讨论了在中枢神经系统药物研究中调查BDEV货物作为机制生物标志物的研究,重点是靶点参与、治疗反应和毒性。此外,我们还讨论了神经科学研究中关于BDEV表征和验证的重要考虑因素和开放性问题。特别强调了BDEV中miRNA货物作为分子读数的使用,突出了它们的稳定性、调节作用以及反映脑功能动态变化的潜力。最后,本综述提出了进一步研究将BDEV miRNA货物用作分子读数的策略,强调了其提供药物作用潜在分子机制见解及其与RDoC框架内中枢神经系统药物发现相关性的能力。尽管存在现有的方法和概念挑战,但BDEV是推进基于RDoC的药物发现的一个有前途的工具。
Neurosci Appl. 2024-12-15
Cochrane Database Syst Rev. 2021-10-27
J Psychiatr Ment Health Nurs. 2024-8
2025-1
J Bone Miner Res. 2024-10-29
Health Technol Assess. 2001
Arch Ital Urol Androl. 2025-6-30
2025-1
Front Vet Sci. 2025-8-20
J Extracell Vesicles. 2024-2
Chem Commun (Camb). 2023-5-30
Acta Neuropathol. 2023-5
Front Psychiatry. 2023-3-9
Int J Biol Sci. 2023